Shots: The US FDA has accepted the sNDA for Lynparza and granted PR status based on P-III PROfound study assessing Lynparza vs hormonal agents (abiraterone or enzalutamide) in patients with […]readmore
Tags : HRR-Mutated Metastatic Castration-Resistant Prostate Cancer